Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Astria Therapeutics ( (ATXS) ) just unveiled an update.
On August 6, 2025, Astria Therapeutics entered into a license agreement with Kaken Pharmaceutical, granting Kaken exclusive rights to develop and commercialize navenibart in Japan for hereditary angioedema. This agreement includes an upfront payment of $16 million and potential additional payments, supporting Astria’s operations into 2028. Kaken will aid in regulatory submissions and reimburse part of the Phase 3 trial costs, enhancing navenibart’s potential as a leading treatment in Japan.
The most recent analyst rating on (ATXS) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Astria Therapeutics stock, see the ATXS Stock Forecast page.
Spark’s Take on ATXS Stock
According to Spark, TipRanks’ AI Analyst, ATXS is a Neutral.
Astria Therapeutics’ stock score reflects its status as a development-stage biotech company. The strong balance sheet provides financial stability, but the lack of revenue and increasing losses pose significant risks. Mixed technical indicators and valuation challenges further contribute to a cautious outlook.
To see Spark’s full report on ATXS stock, click here.
More about Astria Therapeutics
Astria Therapeutics is a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases. Their lead program, navenibart, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Astria also has a program, STAR-0310, in development for atopic dermatitis.
Average Trading Volume: 406,657
Technical Sentiment Signal: Sell
Current Market Cap: $396.2M
Find detailed analytics on ATXS stock on TipRanks’ Stock Analysis page.